Figure 1.
Figure 1. EMCN is highly expressed by HSCs in human adult BM. (A) Microarray GEPs of EMCN in highly purified human hematopoietic BM cell populations including immunophenotypic HSCs (n = 5), MPPs (n = 3), CMPs (n = 7), GMPs (n = 9), MEPs (n = 6), mature neutrophils (polymorphonuclear neutrophils [PMN]; n = 3), and monocytes (Mono; n = 4). One-way analysis of variance (ANOVA) of EMCN expression in HSCs vs MPPs, CMPs, GMPs, MEPs, PMNs, and Monos: P ≤ .0001. (B) Representative gating strategy of viable (7AAD−) human BM populations including all lineage-committed HPCs (L−34+38+; black), HSCs (L−34+38−45RA−90+; green), MPPs (L−34+38−45RA−90−; red), and LMPPs (L−34+38−45RA+90−; blue). (C) Average frequencies (± standard deviation; n = 7) of EMCN+ cells among HSCs (65.1% ± 6.8%), MPPs (26.8% ± 9.5%), LMPPs (11.1% ± 8.1%), HPCs (0.7% ± 0.5%). One-way ANOVA of EMCN+ cells in HSCs vs MPPs, LMPPs, and HPCs: P ≤ .0001.

EMCN is highly expressed by HSCs in human adult BM. (A) Microarray GEPs of EMCN in highly purified human hematopoietic BM cell populations including immunophenotypic HSCs (n = 5), MPPs (n = 3), CMPs (n = 7), GMPs (n = 9), MEPs (n = 6), mature neutrophils (polymorphonuclear neutrophils [PMN]; n = 3), and monocytes (Mono; n = 4). One-way analysis of variance (ANOVA) of EMCN expression in HSCs vs MPPs, CMPs, GMPs, MEPs, PMNs, and Monos: P ≤ .0001. (B) Representative gating strategy of viable (7AAD) human BM populations including all lineage-committed HPCs (L34+38+; black), HSCs (L34+3845RA90+; green), MPPs (L34+3845RA90; red), and LMPPs (L34+3845RA+90; blue). (C) Average frequencies (± standard deviation; n = 7) of EMCN+ cells among HSCs (65.1% ± 6.8%), MPPs (26.8% ± 9.5%), LMPPs (11.1% ± 8.1%), HPCs (0.7% ± 0.5%). One-way ANOVA of EMCN+ cells in HSCs vs MPPs, LMPPs, and HPCs: P ≤ .0001.

Close Modal

or Create an Account

Close Modal
Close Modal